Background: Estrogens are recognized as acting as modulators of pituitary cell renewal, sensitizing cells to mitogenic and apoptotic signals, thus participating in anterior pituitary homeostasis during the estrous cycle. The balance of pro- and antiapoptotic proteins of the Bcl-2 family is known to regulate cell survival and apoptosis. Aims: In order to understand the mechanisms underlying apoptosis during the estrous cycle, we evaluated the expression of the proapoptotic protein Bax and the antiapoptotic proteins Bcl-2 and Bcl-xL in the anterior pituitary gland in cycling female rats as well as the influence of estradiol on the expression of these proteins in anterior pituitary cells of ovariectomized rats. Methods/Results: As determined by Western blot, the expression of Bax was higher in anterior pituitary glands from rats at proestrus than at diestrus I, Bcl-2 protein levels showed no difference and Bcl-xL expression was lower, thus increasing the Bax/Bcl-2 ratio at proestrus. Assessed by annexin V binding and flow cytometry, the percentage of apoptotic anterior pituitary cells was higher in rats at proestrus than at diestrus I. Chronic estrogen treatment in ovariectomized rats enhanced the Bax/Bcl-2 ratio and induced apoptosis. Moreover, incubation of cultured anterior pituitary cells from ovariectomized rats with 17β-estradiol for 24 h increased the Bax/Bcl-2 ratio, decreased Bcl-xL expression and induced apoptosis. Conclusion: Our results demonstrate that estradiol increases the ratio between proapoptotic and antiapoptotic proteins of the Bcl-2 family. This effect could participate in the sensitizing action of estrogens to proapoptotic stimuli and therefore be involved in the high apoptotic rate observed at proestrus in the anterior pituitary gland.

Keywords:
Bax/Bcl-2, Estrogens, Estrous cycle, Pituitary gland, Apoptosis
1.
Oishi Y, Okuda M, Takahashi H, Fujii T, Morii S: Cellular proliferation in the anterior pituitary gland of normal adult rats: influences of sex, estrous cycle, and circadian change. Anat Rec 1993;235:111–120.
2.
Hashi A, Mazawa S, Kato J, Arita J: Pentobarbital anesthesia during the proestrous afternoon blocks lactotroph proliferation occurring on estrus in female rats. Endocrinology 1995;136:4665–4471.
3.
Freeman ME: The neuroendocrine control of the ovarian cycle of the rat; in Knobil E, Neill JD (eds): The Physiology of Reproduction. New York. Raven Press 1994, vol 2, pp 613–658.
4.
Candolfi M, Jaita G, Zaldivar V, Zarate S, Ferrari L, Pisera D, Castro MG, Seilicovich A: Progesterone antagonizes the permissive action of estradiol on tumor necrosis factor-alpha-induced apoptosis of anterior pituitary cells. Endocrinology 2005;146:736–743.
5.
Candolfi M, Zaldivar V, De Laurentiis A, Jaita G, Pisera D, Seilicovich A: TNF-alpha induces apoptosis of lactotropes from female rats. Endocrinology 2002;143:3611–3617.
6.
Jaita G, Candolfi M, Zaldivar V, Zárate S, Ferrari L, Pisera D, Castro MG, Seilicovich A: Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology 2005;146:4737–4744.
7.
Pisera D, Candolfi M, Navarra S, Ferraris J, Zaldivar V, Jaita G, Castro MG, Seilicovich A: Estrogens sensitize anterior pituitary gland to apoptosis. Am J Physiol Endocrinol Metab 2004;287:767–771.
8.
Denef C: Paracrine control of lactotrope proliferation and differentiation. Trends Endocrinol Metab 2003;14:188–195.
9.
Lee EJ, Duan WR, Jakacka M, Gehm BD, Jameson JL: Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 2001;142:3756–3763.
10.
Kawashima K, Yamakawa K, Takahashi W, Takizawa S, Yin P, Sugiyama N, Kanba S, Arita J: The estrogen-occupied estrogen receptor functions as a negative regulator to inhibit cell proliferation induced by insulin/IGF-1: a cell context-specific antimitogenic action of estradiol on rat lactotrophs in culture. Endocrinology 2002;143:2750–2758.
11.
Gutiérrez S, De Paul AL, Petiti JP, del Valle Sosa L, Palmeri CM, Soaje M, Orgnero EM, Torres AI: Estradiol interacts with insulin through membrane receptors to induce an antimitogenic effect on lactotroph cells. Steroids 2008;73:515–527.
12.
Peter ME, Krammer PH: The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26–35.
13.
Kroemer G, Galluzzi L, Brenner C: Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007;87:99–163.
14.
Cory S, Huang DC, Adams JM, Strasser A: Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 1997;14:405–414.
15.
Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SC , Fesik SW: X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 1996;381:335–341.
16.
Suzuki M, Youle RJ, Tjandra N: Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000;103:645–654.
17.
Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW: Solution structure of the antiapoptotic protein bcl-2. Proc Natl Acad Sci USA 2001;98:3012–3017.
18.
Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DCS, Day CL: The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003;22:1497–1507.
19.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ: BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705–711.
20.
Chao DT, Korsmeyer SJ: BCL-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395–419.
21.
Hashi A, Mazawa S, Chen SY, Yamakawa K, Kato J, Arita J: Estradiol-induced diurnal changes in lactotroph proliferation and their hypothalamic regulation in ovariectomized rats. Endocrinology 1996;137:3246–3252.
22.
Kepp O, Rajalingam K, Kimmig S, Rudel T: Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis. EMBO J 2007;26:825–834.
23.
Grinstein E, Du Y, Santourlidis S, Christ J, Uhrberg M, Wernet P: Nucleolin regulates gene expression in CD34-positive hematopoietic cells. J Biol Chem 2007;282:12439–12449.
24.
Souvannavong V, Lemaire C, Chaby R: Lipopolysaccharide protects primary B lymphocytes from apoptosis by preventing mitochondrial dysfunction and bax translocation to mitochondria. Infect Immun 2004;72:3260–3266.
25.
Pavlović V, Cekić S, Kocić G, Sokolović D, Zivković V: Effect of monosodium glutamate on apoptosis and Bcl-2/Bax protein level in rat thymocyte culture. Physiol Res 2007;56:619–626.
26.
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609–619.
27.
Jordan VC: Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004;5:207–213.
28.
Santen RJ, Allred DC: The estrogen paradox. Nat Clin Pract Endocrinol Metab 2007;3:496–497.
29.
Manolagas SC, Kousteni S, Jilka RL: Sex steroids and bone. Recent Prog Horm Res 2002;57:385–409.
30.
Yang Z, Cheng B, Song J, Wan Y, Wang Q, Cheng B, Chen X: Estrogen accelerates G1 to S phase transition and induces a G2/M phase-predominant apoptosis in synthetic vascular smooth muscle cells. Int J Cardiol 2007;118:381–388.
31.
Subramanian M, Shaha C: Up-regulation of Bcl-2 through ERK phosphorylation is associated with human macrophage survival in an estrogen microenvironment. J Immunol 2007;179:2330–2338.
32.
Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC: Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746–1759.
33.
Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 1999;274:32099–32107.
34.
Perillo B, Sasso A, Abbondanza C, Palumbo G: 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000;20:2890–2901.
35.
Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, Kousteni S, Bellido T, Manolagas SC: Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti- versus pro-apoptotic effects of estrogens. J Biol Chem 2005;280:4632-4638.
36.
Theas MS, De Laurentis A, Lasaga M, Pisera D, Duvilanski BH, Seilcovich A: Effect of lipopolysaccharide on tumor necrosis factor and prolactin release from rat anterior pituitary cells. Endocrine 1998;8:241–245.
37.
Evan G, Littlewood T: A matter of life and cell death. Science 1998;281:1317–1322.
38.
Nolan LA, Levy A: Temporally sensitive trophic responsiveness of the adrenalectomized rat anterior pituitary to dexamethasone challenge: relationship between mitotic activity and apoptotic sensitivity. Endocrinology 2003;144:212–219.
39.
Nolan LA, Levy A: The effects of testosterone and oestrogen on gonadectomised and intact male rat anterior pituitary mitotic and apoptotic activity. J Endocrinol 2006;188:387–396.
40.
Butt AJ, Firth SM, King MA, Baxter RC: Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 2000;275:39174–39181.
41.
Luo Y, Waladali W, Li S, Zheng X, Hu L, Zheng H, Hu W, Chen Ch: Estradiol affects proliferation and apoptosis of rat prostatic smooth muscle cells by modulating cell cycle transition and related proteins. Cell Biol Int 2008;32:899–905.
42.
Mitchner NA, Garlick C, Ben-Jonathan N: Cellular distribution and gene regulation of estrogen receptors alpha and beta in the rat pituitary gland. Endocrinology 1998;139:3976–3983.
43.
Shupnik MA: Oestrogen receptors, receptor variants and oestrogen actions in the hypothalamic-pituitary axis. J Neuroendocrinol 2002;14:85–94.
44.
Piva R, Penolazzi L, Lambertini E, Giordano S, Gambari R: Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis 2005;10:1079–1094.
45.
Radl DB, Zárate S, Jaita G, Ferraris J, Zaldivar V, Eijo G, Seilicovich A, Pisera D: Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. Neuroendocrinology 2008;88:43–52.
46.
Kulig E, Camper SA, Kuecker S, Jin L, Lloyd RV: Remodeling of hyperplastic pituitaries in hypothyroid us-subunit knockout mice after thyroxine and 17β-estradiol treatment: role of apoptosis. Endocr Pathol 1998;9:261–274.
47.
Yin P, Arita J: Proestrous surge of gonadotropin-releasing hormone secretion inhibits apoptosis of anterior pituitary cells in cycling female rats. Neuroendocrinology 2002;76:272–282.
48.
Candolfi M, Zaldivar V, Jaita G, Seilicovich A: Anterior pituitary cell renewal during the estrous cycle. Front Horm Res 2006;35:9–21.
49.
Nolan LA, Kavanagh E, Lightman SL, Levy A: Anterior pituitary cell population control: basal cell turnover and the effects of adrenalectomy and dexamethasone treatment. J Neuroendocrinol 1998;10:207–215.
50.
Freeman M, Kanyicska B, Lerant A, Nagy G: Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523–1631.
51.
Ishida M, Takahashi W, Itoh S, Shimodaira S, Maeda S, Arita J: Estrogen actions on lactotroph proliferation are independent of a paracrine interaction with other pituitary cell types: a study using lactotroph-enriched cells. Endocrinology 2007;148:3131–3139.
52.
Wang DG, Johnston CF, Atkinson AB, Heaney AP, Mirakhur M, Buchanan KD: Expression of bcl-2 oncoprotein in pituitary tumours: comparison with c-myc. J Clin Pathol 1996;49:795–797.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.